Clinical Cancer Research
Blood test panel better distinguished pancreatic cancer cases
The leading panel scored 96.3 versus 91.7 for a single blood marker on a measure of how well tests separated cancer cases from controls.The leading panel scored 96.3 versus 91.7 for a single blood marker on a measure of how well tests separated cancer cases from controls.
Case-control · 280 peoplePancreatic ductal adenocarcinoma
Who was studied280 adults with or without pancreatic cancer, against serum CA19-9 alone
What changedAUC was higher with the CA19-9/FUT2/3 panel than serum CA19-9 alone: 96.3 against 91.7
The catchOnly 20 of the 140 pancreatic cancer cases were stage I